TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 74.6%

Neg 0% Neu 74.6% Pos 0%

TD Cowen analyst Tara Bancroft initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating.

Comments

No comments yet. Be the first!